StrandAdvantage 56 Gene Test is a Next Generation Sequencing based test which profiles a patient’s tumor genotype in order to detect genetic alterations in the hot spot regions in a comprehensive panel of well curated 56 tumor genes that may have bearing on prognosis and/or therapeutic options and may allow a doctor and/or to consider various lines of targeted treatment for the patient.